AbCellera Biologics (ABCL)

• Market cap: $2.23B
• 1 day: 2.68%
• 5 days: -4.83%
• 1 month: 37.55%
• 3 months: 111.92%
• 6 months: 66.82%
• Year to date: 112.54%
• 1 year: 72.75%
• 5 years: -62.36%
• 10 years: -87.62%
• Sector: Healthcare
• Industry: Biotechnology

About: AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Employees: 562